Copyright
©The Author(s) 2025.
World J Gastroenterol. Jun 14, 2025; 31(22): 106937
Published online Jun 14, 2025. doi: 10.3748/wjg.v31.i22.106937
Published online Jun 14, 2025. doi: 10.3748/wjg.v31.i22.106937
Table 4 Advanced fibrosis and diabetes
| Group | Total patients | Advanced fibrosis | Diabetes | Advanced fibrosis and diabetes |
| S0 | 21 | 0/21 (0.0) | 0/21 (0.0) | 0/21 (0.0) |
| S1-S3 | 53 | 6/53 (11.3) | 13/53 (24.5) | 5/53 (9.4) |
| S3 | 19 | 3/19 (15.8) | 9/19 (47.4) | 3/19 (15.8) |
| S0-S2 | 55 | 3/55 (5.5) | 4/55 (7.3) | 2/55 (3.6) |
| S1-S2 | 34 | 3/34 (8.8) | 4/34 (11.8) | 2/34 (5.9) |
- Citation: Trifylli EM, Angelakis A, Kriebardis AG, Papadopoulos N, Fortis SP, Pantazatou V, Koskinas J, Kranidioti H, Koustas E, Sarantis P, Manolakopoulos S, Deutsch M. Extracellular vesicles as biomarkers for metabolic dysfunction-associated steatotic liver disease staging using explainable artificial intelligence. World J Gastroenterol 2025; 31(22): 106937
- URL: https://www.wjgnet.com/1007-9327/full/v31/i22/106937.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i22.106937